Long-Term Safety and Efficacy of Janus kinase (JAK) Inhibitors in the Treatment of Rheumatoid Arthritis
Disease Control in Rheumatoid Arthritis with JAK Inhibitors
DOI:
https://doi.org/10.69750/dmls.01.04.039Keywords:
Rheumatoid Arthritis, JAK Inhibitors, Long-term Safety, Efficacy, Disease Activity, Adverse EventsAbstract
Background: Janus kinase (JAK) inhibitors are a new class of drugs for the treatment of rheumatoid arthritis (RA); however, the long-term consequences of using these drugs are still not well understood.
Objective: The primary objective of this research was to examine the effectiveness and safety of JAK inhibitors for the management of rheumatoid arthritis (RA) patients.
Methodology: Clinical raw data of 150 RA patients receiving JAK inhibitors was collected in different tertiary care hospitals in Lahore, Pakistan from March 2023 to June 2024. till were conducted. The anti-inflammatory effect was evaluated by the Disease Activity Score in 28 joints (DAS28) and the safety profile through adverse events, laboratory markers, and patients self-reported outcomes. The SPSS version 27 applied for raw data analysis which used the paired t-tests and multiple regression models to establish the factors that determine favorable outcomes and complications.
Results: JAK inhibitors also reduced the DAS28 scores from baseline to 24 months by a mean of 3. 2 ± 1. 1 (p<0. 001). The findings stated that 12 percent of the patients at baseline and 45 percent of the patients at 24 months had achieved remission. The reported side effects were infections, 25%; gastrointestinal problems, 18%; and abnormal liver function tests, 10%. Severe adverse reactions were noted in 5% of the patients and no new safety issues were observed over the course of the treatment.
Conclusion: JAK inhibitors have been shown to be useful in decreasing the activity of RA for the long-term use with reasonable side effects. The results provided evidence that JAK inhibitors were best treatment of rheumatoid arthritis (RA) but for best efficacy results closely monitoring and specific approach should be applied.
Downloads
References
Iwata S, Tanaka Y. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Review of Clinical Immunology. 2016;12(10):1047-57.doi: 10.1080/1744666X.2016.1189826
Weng C, Xue L, Wang Q, Lu W, Xu J, Liu Z. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. Therapeutic Advances in Musculoskeletal Disease. 2021;13:1759720X21999564.doi: 10.11 77/1759720x21999564
Martinez-Molina C, Gich I, Diaz-Torné C, Park HS, Feliu A, Vidal S, et al. Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Scientific Reports. 2024;14(1):172. doi: 10.1038/s41598-023-50379-8
Liao X, Huo W, Zeng W, Qin F, Dong F, Wei W, et al. Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial. Advances in Rheumatology. 2023;63(1):50.doi: 10.1186/s42358-023-00331-1
Venetsanopoulou AI, Voulgari PV, Drosos AA. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Review of Clinical Immunology. 2022;18(5):485-93.doi: 10.1080/1744666X.2022.2064275
Langbour C, Rene J, Goupille P, Carvajal Alegria G. Efficacy of Janus kinase inhibitors in rheumatoid arthritis. Inflammation Research. 2023;72(5):1121-32.doi:10.1007/s00011-023-017 17-z
Farnos C, Barbier V, Doussiere M, Deprez V, Hamidou Y, Bruy PA, et al. Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study. Journal of Clinical Medicine [Internet]. 2024; 13(16).doi: 10.3390/jcm13164608
Lanzillotta M, Boffini N, Barone E, Cincinelli G, Gerardi MC, Luciano N, et al. Safety of Janus Kinase Inhibitors: A Real-World Multicenter Retrospective Cohort Study. The Journal of Rheumatology. 2023;50(12):1581-6.doi: 10.3899/jrheum.2023-0145
Núñez P, Quera R, Yarur AJ. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. Drugs. 2023;83(4):299-314.doi: 10.100 7/s40265-023-01840-5
Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE, et al. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nature Reviews Rheumatology. 2024;20(2):101-15.doi: 10.1038/s41584-023-010 62-9
Calvo-Garcia A, Ramírez Herráiz E, Llorente Cubas IM, Varas De Dios B, Benedí González J, Morell Baladrón A, et al. The Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study. Journal of Clinical Medicine [Internet]. 2024; 13(9).doi: 10.3390/jcm13092517
Nash P, Lim I, Marabani M. A comparison of Janus kinase inhibitor safety in rheumatoid arthritis. International Journal of Rheumatic Diseases.2021;24(S1):3-14.doi:10.1111/1756-185X.14127
Wang F, Tang X, Zhu M, Mao H, Wan H, Luo F. Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis. Journal of Clinical Medicine. 2022; 11(15).doi: 10.3390/jcm11154459
Li S, Li F, Mao N, Wang J, Xie X. Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: A systematic review and meta-analysis. European Journal of Internal Medicine. 2022;102:47-53.doi:10.1016/j.ejim. 2022.04.007
Harkins P, Burke E, Swales C, Silman A, Conway R. Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis. International Journal of Rheumatic Diseases. 2023;26(1):31-42.doi:10.1111/1756-185X.14447
Hayashi S, Nakano N, Tsubosaka M, Kamenaga T, Kuroda Y, Matsumoto T, et al. Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis. Clinical Rheumatology. 2024.doi: 10.1007/s10067-024-07117-w
Wei Q, Wang H, Zhao J, Luo Z, Wang C, Zhu C, et al. Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis. Frontiers in Pharmacology. 2023;14.doi: 10.3389/fphar.2023.1237234
Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Song Y-W, Chen Y-H, et al. Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan. Rheumatology and Therapy. 2021;8(1):425-42.doi: 10.1007/s40744-021-00280-5
Scheepers L, Yang Y, Chen YL, Jones G. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study. Seminars in Arthritis and Rheumatism. 2024;64: 152314.doi:10.1016/j.semarthrit.2023.152314
Liu L, Yan Y-D, Shi F-H, Lin H-W, Gu Z-C, Li J. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis. Frontiers in Immunology. 2022;13.doi: 10.3389/fimmu.2022.977265
Dyab NE, Al Hurh AA, Knifaty AM, Mahdy EW. Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Sch Bull. 2024;10(7):174-85.
Downloads
PlumX Metrics
Published
Issue
Section
License
Copyright (c) 2024 DEVELOPMENTAL MEDICO-LIFE-SCIENCES
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/public domain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
